Skip to main content
Erschienen in: Abdominal Radiology 12/2023

16.09.2023 | Review

Understanding the role of radiologists in complex treatment decisions for patients with hepatocellular carcinoma

verfasst von: Omar Kamal, Natally Horvat, Sandeep Arora, Humaira Chaudhry, Mohab Elmohr, Lokesh Khanna, Pankaj Sharma Nepal, Manida Wungjramirun, Sadhna B. Nandwana, Anuradha S. Shenoy-Bhangle, James Lee, Ania Kielar, Robert Marks, Khaled Elsayes, Alice Fung

Erschienen in: Abdominal Radiology | Ausgabe 12/2023

Einloggen, um Zugang zu erhalten

Abstract

Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver and represents a significant global health burden. Management of HCC can be challenging due to multiple factors, including variable expectations for treatment outcomes. Several treatment options are available, each with specific eligibility and ineligibility criteria, and are provided by a multidisciplinary team of specialists. Radiologists should be aware of the types of treatment options available, as well as the criteria guiding the development of individualized treatment plans. This awareness enables radiologists to contribute effectively to patient-centered multidisciplinary tumor boards for HCC and play a central role in reassessing care plans when the treatment response is deemed inadequate. This comprehensive review aims to equip radiologists with an overview of HCC staging systems, treatment options, and eligibility criteria. The review also discusses the significance of imaging in HCC diagnosis, treatment planning, and monitoring treatment response. Furthermore, we highlight the crucial branch points in the treatment decision-making process that depend on radiological interpretation.

Graphical abstract

Literatur
1.
Zurück zum Zitat Konyn, P., A. Ahmed, and D. Kim, Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol, 2021. 15(11): p. 1295-1307.PubMedCrossRef Konyn, P., A. Ahmed, and D. Kim, Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol, 2021. 15(11): p. 1295-1307.PubMedCrossRef
2.
Zurück zum Zitat Kulik, L. and H.B. El-Serag, Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology, 2019. 156(2): p. 477-491 e1.PubMedCrossRef Kulik, L. and H.B. El-Serag, Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology, 2019. 156(2): p. 477-491 e1.PubMedCrossRef
3.
Zurück zum Zitat Ayuso, C., et al., Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol, 2018. 101: p. 72-81.PubMedCrossRef Ayuso, C., et al., Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol, 2018. 101: p. 72-81.PubMedCrossRef
4.
Zurück zum Zitat Reig, M., et al., BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol, 2022. 76(3): p. 681-693.PubMedCrossRef Reig, M., et al., BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol, 2022. 76(3): p. 681-693.PubMedCrossRef
5.
Zurück zum Zitat Amorim, J., et al., Critical review of HCC imaging in the multidisciplinary setting: treatment allocation and evaluation of response. Abdom Radiol (NY), 2020. 45(10): p. 3119-3128.PubMedCrossRef Amorim, J., et al., Critical review of HCC imaging in the multidisciplinary setting: treatment allocation and evaluation of response. Abdom Radiol (NY), 2020. 45(10): p. 3119-3128.PubMedCrossRef
6.
Zurück zum Zitat Sinn, D.H., et al., Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. PLoS One, 2019. 14(1): p. e0210730.PubMedPubMedCentralCrossRef Sinn, D.H., et al., Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. PLoS One, 2019. 14(1): p. e0210730.PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Shenoy-Bhangle, A.S., et al., Role of the radiologist at HCC multidisciplinary conference and use of the LR-TR algorithm for improving workflow. Abdom Radiol (NY), 2021. 46(8): p. 3558-3564.PubMedCrossRef Shenoy-Bhangle, A.S., et al., Role of the radiologist at HCC multidisciplinary conference and use of the LR-TR algorithm for improving workflow. Abdom Radiol (NY), 2021. 46(8): p. 3558-3564.PubMedCrossRef
8.
Zurück zum Zitat Amin, M.B., et al., The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin, 2017. 67(2): p. 93-99.PubMedCrossRef Amin, M.B., et al., The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin, 2017. 67(2): p. 93-99.PubMedCrossRef
9.
Zurück zum Zitat Wiesner, R., et al., Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology, 2003. 124(1): p. 91-6.PubMedCrossRef Wiesner, R., et al., Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology, 2003. 124(1): p. 91-6.PubMedCrossRef
10.
Zurück zum Zitat Galle, P.R., et al., Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int, 2019. 39(12): p. 2214-2229.PubMedCrossRef Galle, P.R., et al., Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int, 2019. 39(12): p. 2214-2229.PubMedCrossRef
11.
Zurück zum Zitat Tangkijvanich, P., et al., Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol, 2000. 31(4): p. 302-8.PubMedCrossRef Tangkijvanich, P., et al., Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol, 2000. 31(4): p. 302-8.PubMedCrossRef
12.
Zurück zum Zitat Ikai, I., et al., Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer, 2004. 101(4): p. 796-802.PubMedCrossRef Ikai, I., et al., Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer, 2004. 101(4): p. 796-802.PubMedCrossRef
13.
Zurück zum Zitat Mehta, N., et al., Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant, 2018. 18(5): p. 1206-1213.PubMedCrossRef Mehta, N., et al., Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant, 2018. 18(5): p. 1206-1213.PubMedCrossRef
14.
Zurück zum Zitat Pusceddu, C., et al., The Increasing Role of CT-Guided Cryoablation for the Treatment of Liver Cancer: A Single-Center Report. Cancers (Basel), 2022. 14(12).PubMedCrossRef Pusceddu, C., et al., The Increasing Role of CT-Guided Cryoablation for the Treatment of Liver Cancer: A Single-Center Report. Cancers (Basel), 2022. 14(12).PubMedCrossRef
15.
Zurück zum Zitat Han, J., Y.C. Fan, and K. Wang, Radiofrequency ablation versus microwave ablation for early stage hepatocellular carcinoma: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore), 2020. 99(43): p. e22703.PubMedCrossRef Han, J., Y.C. Fan, and K. Wang, Radiofrequency ablation versus microwave ablation for early stage hepatocellular carcinoma: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore), 2020. 99(43): p. e22703.PubMedCrossRef
16.
Zurück zum Zitat Musick, J.R., et al., Laparoscopic microwave ablation versus percutaneous microwave ablation of hepatic malignancies: Efficacy and recurrence-free survival outcomes in patients. Surgery, 2023. 173(3): p. 598-602.PubMedCrossRef Musick, J.R., et al., Laparoscopic microwave ablation versus percutaneous microwave ablation of hepatic malignancies: Efficacy and recurrence-free survival outcomes in patients. Surgery, 2023. 173(3): p. 598-602.PubMedCrossRef
17.
Zurück zum Zitat Cucchetti, A., et al., Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol, 2013. 59(2): p. 300-7.PubMedCrossRef Cucchetti, A., et al., Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol, 2013. 59(2): p. 300-7.PubMedCrossRef
18.
Zurück zum Zitat Cho, Y.K., et al., Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology, 2010. 51(4): p. 1284-90.PubMedCrossRef Cho, Y.K., et al., Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology, 2010. 51(4): p. 1284-90.PubMedCrossRef
19.
Zurück zum Zitat Fuks, D., et al., Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis. Hepatology, 2012. 55(1): p. 132-40.PubMedCrossRef Fuks, D., et al., Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis. Hepatology, 2012. 55(1): p. 132-40.PubMedCrossRef
20.
Zurück zum Zitat Berzigotti, A., et al., Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology, 2015. 61(2): p. 526-36.PubMedCrossRef Berzigotti, A., et al., Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology, 2015. 61(2): p. 526-36.PubMedCrossRef
21.
Zurück zum Zitat Ferrer-Fabrega, J., et al., Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. Hepatology, 2016. 63(3): p. 839-49.PubMedCrossRef Ferrer-Fabrega, J., et al., Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. Hepatology, 2016. 63(3): p. 839-49.PubMedCrossRef
22.
Zurück zum Zitat Mazzaferro, V., et al., Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med, 1996. 334(11): p. 693-9.PubMedCrossRef Mazzaferro, V., et al., Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med, 1996. 334(11): p. 693-9.PubMedCrossRef
23.
Zurück zum Zitat Machicao, V.I., Model for End-Stage Liver Disease-Sodium Score: The Evolution in the Prioritization of Liver Transplantation. Clin Liver Dis, 2017. 21(2): p. 275-287.PubMedCrossRef Machicao, V.I., Model for End-Stage Liver Disease-Sodium Score: The Evolution in the Prioritization of Liver Transplantation. Clin Liver Dis, 2017. 21(2): p. 275-287.PubMedCrossRef
24.
Zurück zum Zitat Kloeckner, R., P.R. Galle, and J. Bruix, Local and Regional Therapies for Hepatocellular Carcinoma. Hepatology, 2021. 73 Suppl 1: p. 137-149.PubMedCrossRef Kloeckner, R., P.R. Galle, and J. Bruix, Local and Regional Therapies for Hepatocellular Carcinoma. Hepatology, 2021. 73 Suppl 1: p. 137-149.PubMedCrossRef
25.
Zurück zum Zitat Couri, T. and A. Pillai, Goals and targets for personalized therapy for HCC. Hepatol Int, 2019. 13(2): p. 125-137.PubMedCrossRef Couri, T. and A. Pillai, Goals and targets for personalized therapy for HCC. Hepatol Int, 2019. 13(2): p. 125-137.PubMedCrossRef
26.
Zurück zum Zitat Guiu, B., et al., TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC. Cardiovasc Intervent Radiol, 2022. 45(11): p. 1599-1607.PubMedCrossRef Guiu, B., et al., TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC. Cardiovasc Intervent Radiol, 2022. 45(11): p. 1599-1607.PubMedCrossRef
27.
Zurück zum Zitat Lewandowski, R.J., et al., A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant, 2009. 9(8): p. 1920-8.PubMedCrossRef Lewandowski, R.J., et al., A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant, 2009. 9(8): p. 1920-8.PubMedCrossRef
28.
Zurück zum Zitat Gabr, A., et al., Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort. Hepatology, 2021. 73(3): p. 998-1010.PubMedCrossRef Gabr, A., et al., Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort. Hepatology, 2021. 73(3): p. 998-1010.PubMedCrossRef
29.
Zurück zum Zitat Salem, R., et al., Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology, 2016. 151(6): p. 1155-1163 e2.PubMedCrossRef Salem, R., et al., Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology, 2016. 151(6): p. 1155-1163 e2.PubMedCrossRef
30.
Zurück zum Zitat Gabr, A., et al., Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging, 2021. 48(2): p. 580-583.PubMedCrossRef Gabr, A., et al., Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging, 2021. 48(2): p. 580-583.PubMedCrossRef
32.
Zurück zum Zitat Shampain, K.L., et al., SBRT for HCC: Overview of technique and treatment response assessment. Abdom Radiol (NY), 2021. 46(8): p. 3615-3624.PubMedCrossRef Shampain, K.L., et al., SBRT for HCC: Overview of technique and treatment response assessment. Abdom Radiol (NY), 2021. 46(8): p. 3615-3624.PubMedCrossRef
33.
Zurück zum Zitat Lasley, F.D., et al., Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Pract Radiat Oncol, 2015. 5(5): p. e443-e449.PubMedCrossRef Lasley, F.D., et al., Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Pract Radiat Oncol, 2015. 5(5): p. e443-e449.PubMedCrossRef
34.
Zurück zum Zitat Benson, A.B., et al., Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2021. 19(5): p. 541-565.PubMedCrossRef Benson, A.B., et al., Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2021. 19(5): p. 541-565.PubMedCrossRef
35.
Zurück zum Zitat Cannon, R., et al., Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol, 2013. 107(5): p. 544-9.PubMedCrossRef Cannon, R., et al., Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol, 2013. 107(5): p. 544-9.PubMedCrossRef
36.
Zurück zum Zitat Lu, D.S., et al., Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology, 2005. 234(3): p. 954-60.PubMedCrossRef Lu, D.S., et al., Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology, 2005. 234(3): p. 954-60.PubMedCrossRef
37.
Zurück zum Zitat Bhutiani, N., et al., Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC). HPB (Oxford), 2016. 18(7): p. 593-9.PubMedCrossRef Bhutiani, N., et al., Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC). HPB (Oxford), 2016. 18(7): p. 593-9.PubMedCrossRef
38.
Zurück zum Zitat Zou, Y.W., et al., The latest research progress on minimally invasive treatments for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int, 2023. 22(1): p. 54-63.PubMedCrossRef Zou, Y.W., et al., The latest research progress on minimally invasive treatments for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int, 2023. 22(1): p. 54-63.PubMedCrossRef
39.
40.
Zurück zum Zitat Chernyak, V., et al., Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology, 2018. 289(3): p. 816-830.PubMedCrossRef Chernyak, V., et al., Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology, 2018. 289(3): p. 816-830.PubMedCrossRef
41.
Zurück zum Zitat Eisenbrey, J.R., et al., Contrast-enhanced ultrasound (CEUS) in HCC diagnosis and assessment of tumor response to locoregional therapies. Abdom Radiol (NY), 2021. 46(8): p. 3579-3595.PubMedCrossRef Eisenbrey, J.R., et al., Contrast-enhanced ultrasound (CEUS) in HCC diagnosis and assessment of tumor response to locoregional therapies. Abdom Radiol (NY), 2021. 46(8): p. 3579-3595.PubMedCrossRef
42.
43.
Zurück zum Zitat Kambadakone, A.R., et al., LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound. Abdom Radiol (NY), 2018. 43(1): p. 56-74.PubMedCrossRef Kambadakone, A.R., et al., LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound. Abdom Radiol (NY), 2018. 43(1): p. 56-74.PubMedCrossRef
45.
Zurück zum Zitat Toniutto, P., et al., Liver Transplantation in Patients with Hepatocellular Carcinoma beyond the Milan Criteria: A Comprehensive Review. J Clin Med, 2021. 10(17).PubMedPubMedCentralCrossRef Toniutto, P., et al., Liver Transplantation in Patients with Hepatocellular Carcinoma beyond the Milan Criteria: A Comprehensive Review. J Clin Med, 2021. 10(17).PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Seuss, C.R., et al., Comparison of MRI pulse sequences for prediction of size of hepatocellular carcinoma at explant evaluation. AJR Am J Roentgenol, 2014. 203(2): p. 300-5.PubMedCrossRef Seuss, C.R., et al., Comparison of MRI pulse sequences for prediction of size of hepatocellular carcinoma at explant evaluation. AJR Am J Roentgenol, 2014. 203(2): p. 300-5.PubMedCrossRef
47.
Zurück zum Zitat Dietrich, O., et al., Technical aspects of MR diffusion imaging of the body. European Journal of Radiology, 2010. 76(3): p. 314-322.PubMedCrossRef Dietrich, O., et al., Technical aspects of MR diffusion imaging of the body. European Journal of Radiology, 2010. 76(3): p. 314-322.PubMedCrossRef
48.
Zurück zum Zitat Jha, R.C., S.S. Khera, and A.D. Kalaria, Portal Vein Thrombosis: Imaging the Spectrum of Disease With an Emphasis on MRI Features. AJR Am J Roentgenol, 2018. 211(1): p. 14-24.PubMedCrossRef Jha, R.C., S.S. Khera, and A.D. Kalaria, Portal Vein Thrombosis: Imaging the Spectrum of Disease With an Emphasis on MRI Features. AJR Am J Roentgenol, 2018. 211(1): p. 14-24.PubMedCrossRef
49.
Zurück zum Zitat Sherman, C.B., et al., Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria. Liver Transpl, 2019. 25(2): p. 207-216.PubMedPubMedCentralCrossRef Sherman, C.B., et al., Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria. Liver Transpl, 2019. 25(2): p. 207-216.PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Kawagishi, N., HCC with portal vein tumor thrombosis: how to manage? Hepatol Int, 2020. 14(5): p. 609-611.PubMedCrossRef Kawagishi, N., HCC with portal vein tumor thrombosis: how to manage? Hepatol Int, 2020. 14(5): p. 609-611.PubMedCrossRef
51.
Zurück zum Zitat Hatano, E., et al., Significance of hepatic resection and adjuvant hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus in the first branch of portal vein and the main portal trunk: a project study for hepatic surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci, 2018. 25(9): p. 395-402.PubMedCrossRef Hatano, E., et al., Significance of hepatic resection and adjuvant hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus in the first branch of portal vein and the main portal trunk: a project study for hepatic surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci, 2018. 25(9): p. 395-402.PubMedCrossRef
52.
Zurück zum Zitat Kokudo, T., et al., Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol, 2016. 65(5): p. 938-943.PubMedCrossRef Kokudo, T., et al., Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol, 2016. 65(5): p. 938-943.PubMedCrossRef
53.
Zurück zum Zitat Lau, W.Y., et al., Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology, 2013. 84(5): p. 311-8.PubMedCrossRef Lau, W.Y., et al., Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology, 2013. 84(5): p. 311-8.PubMedCrossRef
54.
Zurück zum Zitat Xu, Y.C., F. Yang, and D.L. Fu, Clinical significance of variant hepatic artery in pancreatic resection: A comprehensive review. World J Gastroenterol, 2022. 28(19): p. 2057-2075.PubMedPubMedCentralCrossRef Xu, Y.C., F. Yang, and D.L. Fu, Clinical significance of variant hepatic artery in pancreatic resection: A comprehensive review. World J Gastroenterol, 2022. 28(19): p. 2057-2075.PubMedPubMedCentralCrossRef
55.
Zurück zum Zitat Entezari, P., et al., Promoting Surgical Resection through Future Liver Remnant Hypertrophy. Radiographics, 2022. 42(7): p. 2166-2183.PubMedCrossRef Entezari, P., et al., Promoting Surgical Resection through Future Liver Remnant Hypertrophy. Radiographics, 2022. 42(7): p. 2166-2183.PubMedCrossRef
56.
Zurück zum Zitat Lian, D., et al., CT volumetry helps predict prognosis of large hepatocellular carcinoma after resection. Clin Radiol, 2022. 77(8): p. e599-e605.PubMedCrossRef Lian, D., et al., CT volumetry helps predict prognosis of large hepatocellular carcinoma after resection. Clin Radiol, 2022. 77(8): p. e599-e605.PubMedCrossRef
57.
Zurück zum Zitat Lim, M.C., et al., CT volumetry of the liver: where does it stand in clinical practice? Clin Radiol, 2014. 69(9): p. 887-95.PubMedCrossRef Lim, M.C., et al., CT volumetry of the liver: where does it stand in clinical practice? Clin Radiol, 2014. 69(9): p. 887-95.PubMedCrossRef
58.
Zurück zum Zitat Forner, A., J.M. Llovet, and J. Bruix, Hepatocellular carcinoma. Lancet, 2012. 379(9822): p. 1245-55.PubMedCrossRef Forner, A., J.M. Llovet, and J. Bruix, Hepatocellular carcinoma. Lancet, 2012. 379(9822): p. 1245-55.PubMedCrossRef
59.
Zurück zum Zitat Uka, K., et al., Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol, 2007. 13(3): p. 414-20.PubMedPubMedCentralCrossRef Uka, K., et al., Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol, 2007. 13(3): p. 414-20.PubMedPubMedCentralCrossRef
60.
Zurück zum Zitat Kielar, A., et al., Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. Abdom Radiol (NY), 2018. 43(1): p. 218-230.PubMedCrossRef Kielar, A., et al., Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. Abdom Radiol (NY), 2018. 43(1): p. 218-230.PubMedCrossRef
61.
Zurück zum Zitat Ram, R., et al., LI-RADS treatment response lexicon: review, refresh and resolve with emerging data. Abdom Radiol (NY), 2021. 46(8): p. 3549-3557.PubMedCrossRef Ram, R., et al., LI-RADS treatment response lexicon: review, refresh and resolve with emerging data. Abdom Radiol (NY), 2021. 46(8): p. 3549-3557.PubMedCrossRef
62.
Zurück zum Zitat Aslam, A., et al., Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. World J Hepatol, 2020. 12(10): p. 738-753.PubMedPubMedCentralCrossRef Aslam, A., et al., Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. World J Hepatol, 2020. 12(10): p. 738-753.PubMedPubMedCentralCrossRef
63.
Zurück zum Zitat Mendiratta-Lala, M., et al., Natural history of hepatocellular carcinoma after stereotactic body radiation therapy. Abdom Radiol (NY), 2020. 45(11): p. 3698-3708.PubMedCrossRef Mendiratta-Lala, M., et al., Natural history of hepatocellular carcinoma after stereotactic body radiation therapy. Abdom Radiol (NY), 2020. 45(11): p. 3698-3708.PubMedCrossRef
64.
Zurück zum Zitat Llovet, J.M. and R. Lencioni, mRECIST for HCC: Performance and novel refinements. J Hepatol, 2020. 72(2): p. 288-306.PubMedCrossRef Llovet, J.M. and R. Lencioni, mRECIST for HCC: Performance and novel refinements. J Hepatol, 2020. 72(2): p. 288-306.PubMedCrossRef
65.
Zurück zum Zitat Ronot, M., et al., Imaging to Predict Prognosis in Hepatocellular Carcinoma: Current and Future Perspectives. Radiology, 2023. 307(3): p. e221429.PubMedCrossRef Ronot, M., et al., Imaging to Predict Prognosis in Hepatocellular Carcinoma: Current and Future Perspectives. Radiology, 2023. 307(3): p. e221429.PubMedCrossRef
66.
Zurück zum Zitat Li, X., et al., Correlations between the minimum and mean apparent diffusion coefficient values of hepatocellular carcinoma and tumor grade. J Magn Reson Imaging, 2016. 44(6): p. 1442-1447.PubMedCrossRef Li, X., et al., Correlations between the minimum and mean apparent diffusion coefficient values of hepatocellular carcinoma and tumor grade. J Magn Reson Imaging, 2016. 44(6): p. 1442-1447.PubMedCrossRef
67.
Zurück zum Zitat Witjes, C.D., et al., Histological differentiation grade and microvascular invasion of hepatocellular carcinoma predicted by dynamic contrast-enhanced MRI. J Magn Reson Imaging, 2012. 36(3): p. 641-7.PubMedCrossRef Witjes, C.D., et al., Histological differentiation grade and microvascular invasion of hepatocellular carcinoma predicted by dynamic contrast-enhanced MRI. J Magn Reson Imaging, 2012. 36(3): p. 641-7.PubMedCrossRef
68.
Zurück zum Zitat Ocal, O., et al., Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma. Br J Cancer, 2022. 126(2): p. 211-218.PubMedCrossRef Ocal, O., et al., Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma. Br J Cancer, 2022. 126(2): p. 211-218.PubMedCrossRef
69.
Zurück zum Zitat Wang, W., et al., The clinical significance of microvascular invasion in the surgical planning and postoperative sequential treatment in hepatocellular carcinoma. Sci Rep, 2021. 11(1): p. 2415.PubMedPubMedCentralCrossRef Wang, W., et al., The clinical significance of microvascular invasion in the surgical planning and postoperative sequential treatment in hepatocellular carcinoma. Sci Rep, 2021. 11(1): p. 2415.PubMedPubMedCentralCrossRef
70.
Zurück zum Zitat Chong, H.H., et al., Multi-scale and multi-parametric radiomics of gadoxetate disodium-enhanced MRI predicts microvascular invasion and outcome in patients with solitary hepatocellular carcinoma </= 5 cm. Eur Radiol, 2021. 31(7): p. 4824-4838.PubMedPubMedCentralCrossRef Chong, H.H., et al., Multi-scale and multi-parametric radiomics of gadoxetate disodium-enhanced MRI predicts microvascular invasion and outcome in patients with solitary hepatocellular carcinoma </= 5 cm. Eur Radiol, 2021. 31(7): p. 4824-4838.PubMedPubMedCentralCrossRef
71.
Zurück zum Zitat Calderaro, J., et al., Molecular and histological correlations in liver cancer. J Hepatol, 2019. 71(3): p. 616-630.PubMedCrossRef Calderaro, J., et al., Molecular and histological correlations in liver cancer. J Hepatol, 2019. 71(3): p. 616-630.PubMedCrossRef
72.
Zurück zum Zitat Kim, G.H., et al., Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective. Korean J Radiol, 2021. 22(11): p. 1822-1833.PubMedPubMedCentralCrossRef Kim, G.H., et al., Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective. Korean J Radiol, 2021. 22(11): p. 1822-1833.PubMedPubMedCentralCrossRef
73.
Zurück zum Zitat Llovet, J.M., et al., Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, 2021. 18(5): p. 293-313.PubMedCrossRef Llovet, J.M., et al., Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, 2021. 18(5): p. 293-313.PubMedCrossRef
Metadaten
Titel
Understanding the role of radiologists in complex treatment decisions for patients with hepatocellular carcinoma
verfasst von
Omar Kamal
Natally Horvat
Sandeep Arora
Humaira Chaudhry
Mohab Elmohr
Lokesh Khanna
Pankaj Sharma Nepal
Manida Wungjramirun
Sadhna B. Nandwana
Anuradha S. Shenoy-Bhangle
James Lee
Ania Kielar
Robert Marks
Khaled Elsayes
Alice Fung
Publikationsdatum
16.09.2023
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 12/2023
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-023-04033-6

Weitere Artikel der Ausgabe 12/2023

Abdominal Radiology 12/2023 Zur Ausgabe

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärztinnen und Psychotherapeuten.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.